Peptic Ulcer Disease( PUD):

30
Peptic Ulcer Disease( PUD): .

description

Peptic Ulcer Disease( PUD):. . Introduction: . Discontinuation of the mucous membrane of the GIT. Acute or chronic; both penetrate the muscularis mucosae but in acute ulcer no evidence of fibrosis. Erosions do not penetrate the muscularis mucosae. - PowerPoint PPT Presentation

Transcript of Peptic Ulcer Disease( PUD):

Page 1: Peptic Ulcer Disease( PUD):

Peptic Ulcer Disease( PUD):.

Page 2: Peptic Ulcer Disease( PUD):

Introduction: Discontinuation of the mucous membrane of the GIT. Acute or chronic; both penetrate the muscularis mucosae

but in acute ulcer no evidence of fibrosis. Erosions do not penetrate the muscularis mucosae. Locations: duodenum, stomach, lower oesophagus, or in

the jejunum after Gastrojejunostomy or, rarely, in the ileum adjacent to a Meckel's diverticulum.

Page 3: Peptic Ulcer Disease( PUD):

GASTRIC & DUODENAL ULCER : The prevalence is decreasing in Western communities as a

result of widespread H. pylori eradication, but high in developing countries.

Male/female for DU 5:1-2:1, for GU is 2:1 or less.

Page 4: Peptic Ulcer Disease( PUD):

Aetiology: H Pylori. NSAIDs. Smoking. Genetics.

Page 5: Peptic Ulcer Disease( PUD):

Aetiology: H pylori The most important cause. HP prevalence rises with age, 50% > 50 years are infected. In developing world HP is much more common, usually

acquired in childhood & up to 90% of the adults are infected.

The vast majority of colonised people remain healthy/ asymptomatic& only a minority develop clinical disease.

90% DU, 70% GU are infected with H. pylori; the remaining 30% GU are due to NSAIDs.

Page 6: Peptic Ulcer Disease( PUD):

H pylori: Pathophysio H. pylori is Gram-negative, spiral with multiple flagella at

one end which make it motile, allowing it to burrow& live deep beneath the mucus layer closely adherent to the epithelial surface.

It uses an adhesin molecule (BabA) to bind to the Lewis b antigen on epithelial cells,where the surface pH is close to neutral & any acidity is buffered by the organism's production of the enzyme urease.produces ammonia from urea, raises the pH around the bacterium & between its two cell membrane layers.

The bacteria spread by person-to-person contact via gastric refluxate or vomitus.

H. pylori exclusively colonises gastric-type epithelium& found in the duodenum only in association if there are patches of gastric metaplasia.

Page 7: Peptic Ulcer Disease( PUD):

H pylori: Pathophysio Causes chronic gastritis by provoking a local

inflammatory response in the underlying epithelium, depends on numerous factors; bacterial factors as expresion of cagA / vacA genes & host factors.

Page 8: Peptic Ulcer Disease( PUD):

H pylori: Pathophysio Bacterial factots: H. pylori strains expressing cagA (cagA+) are more often

associated with disease than cagA- strains. Most strains also secrete a large pore-forming protein

called vacA causes large vacuoles to form in cells in vitro.

Page 9: Peptic Ulcer Disease( PUD):

H pylori: Pathophysio Host factors: Genetic polymorphisms; for example, greater levels of

expression of the proinflammatory cytokine interleukin-1β (IL-1β) are associated with greater risk of gastric atrophy & subsequent carcinoma &polymorphisms in other genes involved in the host inflammatory response to infection (e.g. IL-10 / TNF-α) may also be important.

Page 10: Peptic Ulcer Disease( PUD):

H pylori: Pathophysio In most people H. pylori causes antral gastritis associated with

depletion of somatostatin (from D cells)& gastrin release from G cells unchecked by somatostatin.

The subsequent hypergastrinaemia stimulates acid production by parietal cells, but in the majority of cases this has no clinical consequences.

In a minority of patients (perhaps smokers) this effect is exaggerated, leading to duodenal ulceration

The role of H. pylori in the pathogenesis of gastric ulcer is less clear but probably acts by reducing gastric mucosal resistance to attack from acid/pepsin.

In 1% of infected people, H. pylori causes a pangastritis leading to gastric atrophy/ hypochlorhydria,allows bacteria to proliferate within the stomach; these may produce mutagenic nitrites from dietary nitrates, predisposing to the development of gastric cancer

Page 11: Peptic Ulcer Disease( PUD):
Page 12: Peptic Ulcer Disease( PUD):
Page 13: Peptic Ulcer Disease( PUD):

Factors which influence the virulence of H. pylori.

Page 14: Peptic Ulcer Disease( PUD):

HP Diagnosis: Urea Breath tests are best because of their accuracy,

simplicity & non-invasiveness.

Page 15: Peptic Ulcer Disease( PUD):

HP Diagnosis: Others Test Advantages Disadvantages

NON-INVASIVE

Serology Rapid office kits available Lacks sensitivity and specificity

  Good for population studies Cannot differentiate current from past infection

Urea breath tests High sensitivity and specificity 14C uses radioactivity

    13C requires expensive mass spectrometer

Faecal antigen test Cheap, accurate Acceptability

INVASIVE (ANTRAL BIOPSY)

Histology Sensitivity and specificity False negatives occur

    Takes several days to process

Rapid urease tests, e.g. CLO, Pyloritek Cheap, quickSpecificity

Lack sensitivity

Microbiological culture 'Gold standard' Slow / laborious

  Defines antibiotic sensitivity Lacks sensitivity

Page 16: Peptic Ulcer Disease( PUD):

Smoking: Smoking confers an increased risk of gastric ulcer & to a

lesser extent, duodenal ulcer. Once the ulcer has formed, it is more likely to cause

complications& less likely to heal if the patient continues to smoke.

NSAIDs

Page 17: Peptic Ulcer Disease( PUD):

Acid-pepsin vs mucosal resistance: Ulcer forms when there is imbalance between aggressive

factors, i.e. acid /pepsin & defensive factors, i.e. gastric /duodenal mucosa, bicarbonte, mucosal blood flow* PGs.

Ulcers occur only in the presence of acid /pepsin; never found in achlorhydric as pernicious anaemia& severe intractable PU nearly always occurs in ZES, characterised by very high acid secretion.

Most DU have markedly exaggerated acid secretion in response to stimulation by gastrin& H. pylori leads to hypergastrinaemia.

In GU the effects of H. pylori are more complex&impaired mucosal defence resulting from a combination of HP, NSAIDs&smoking have a more important role.

Page 18: Peptic Ulcer Disease( PUD):

Gastroduodenal mucosal protection; PG stimulate HCO3 /mucus secretion& increase mucosal blood flow.

Page 19: Peptic Ulcer Disease( PUD):

Clinical features: Chronic with spontaneous relapse /remission lasting for

decades, if not for life. DU/GU share common symptoms. Recurrent abd pain with 3 notable characteristics:

epigastric , episodic & relationship to food . Occasional vomiting occurs in 40%; persistent daily

vomiting suggests GOO. In 1/3 history is less characteristic, esp in elderly on

NSAIDs, pain may be absent or slight epigastric unease. Occasionally, only anorexia / nausea, or a sense of undue

repletion after meals. In some completely 'silent', presenting for the first time

with anaemia, abrupt haematemesis or as acute perforation; recurrent acute bleeding.

The diagnostic value of individual symptoms is poor.

Page 20: Peptic Ulcer Disease( PUD):

Diagnosis: Endoscopy is the preferred investigation. Gastric ulcers may occasionally be malignant& therefore

must always be biopsied & followed up to ensure healing

Page 21: Peptic Ulcer Disease( PUD):

Management: Aims: relieve symptoms, induce healing ,prevent recurrence. H. pylori eradication is the cornerstone of therapy, as this will

successfully prevent relapse& eliminate the need for long-term therapy in the majority.

H. pylori eradication All patients with proven acute or chronic DU &GU who are H. pylori-positive should be offered eradication as primary therapy.

Treatment is PPI simultaneously with two antibiotics (from amoxicillin, clarithromycin , metronidazole) for 7 days.

Success is > 90%, although compliance, side-effects& metronidazole resistance influence the success of therapy.

Second-line therapy should be offered to those patients who remain infected after initial therapy,choice lies between a third attempt with quadruple therapy (bismuth, PPI+ 2 antibiotics) or long-term maintenance therapy with PPI.

Page 22: Peptic Ulcer Disease( PUD):

Management: H. pylori / NSAIDs are independent risk factors for ulcer High risk patients requiring long-term NSAIDs should

first undergo eradication therapy to reduce ulcer risk. This may not be necessary in young, fit patients with no

history of ulcer disease or dyspepsia but a 'test & treat' strategy for older patients with major comorbidity or a previous ulcer history is recommended.

Subsequent co-prescription of PPI+ NSAID is advised but is not always necessary for patients being given low-dose aspirin in whom the risk of ulcer complications is lower

Page 23: Peptic Ulcer Disease( PUD):

COMMON SIDE-EFFECTS OF HP ERADICATION: Diarrhoea

– 30-50%; usually mild but Clostridium difficile-associated colitis can occur.

Flushing & vomiting when taken with alcohol (metronizadole)

Nausea, vomiting Abdominal cramp Headache Rash

Page 24: Peptic Ulcer Disease( PUD):

Other indications OF HP ERADICATION: Definite Peptic ulcer MALToma H. pylori-positive dyspepsia Not indicated Asymptomatic Gastro-oesophageal reflux disease Uncertain Family history of gastric cancer Non-ulcer dyspepsia Low risk Long-term NSAID users

Page 25: Peptic Ulcer Disease( PUD):

General measures: Cigarette smoking, aspirin/ NSAIDs should be avoided. Alcohol in moderation is not harmful. No special dietary advice is required. Short-term management: many different drugs are

available for of acid peptic symptoms. Maintenance treatment: Continuous maintenance

treatment should not be necessary after successful H. pylori eradication.

For the minority who do require it, the lowest effective dose should be used.

Page 26: Peptic Ulcer Disease( PUD):

Group Examples Mechanism Comments

antacid Aluminium hydroxide, magnesium trisilicate, alginic acid

Antacids; alginates form protective mucosal 'raft'

Aluminium salts block digoxin absorption and are constipating while magnesium salts can cause diarrhoea; some have high sodium content and can exacerbate cardiac failure

H2-Bs Ranitidine, cimetidine, famotidine, nizatidine

Competitive inhibitors of H2-receptors on parietal and ECL cells

Less potent than PPIs; good safety profile- some available without prescription; cimetidine may interfere with warfarin and phenytoin metabolism via cytochrome P450

PPI Omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole

Irreversible inhibitors of H+/K+ ATPase on parietal cell surface

Potent acid suppression and rapid ulcer healing; used in H. pylori therapy; superior to H2 antagonists for healing ulcers and oesophagitis

Chelat Tripotassium dicitratobismuthate

Ammoniacal suspension of complex bismuth salt; anti-H. pylori activity and enhances mucosal protection

May darken tongue and stools

C,Salts Sucralfate Aluminium salt of sucrose octasulphate; little effect on acid -may protect ulcer base from peptic activity and enhance epithelial cell turnover

Caution in renal impairment; reports of bezoar formation

PGs Misoprostol Enhance mucosal blood flow, stimulate mucus and bicarbonate secretion; stimulate epithelial proliferation

Diarrhoea; abortifacient-contraindicated in women of child-bearing age

Page 27: Peptic Ulcer Disease( PUD):

ProglumideACh

PGE2Histamine Gastrin

Adenyl cyclase

_ +

ATP cAMP

Protein Kinase (Activated)

Ca++

+

Ca++

Proton pump

KK+ H+

Gastric acid

Parietal cellLumen of stomach

AntacidOmeprazole

Ranitidine

H2M3

Misoprostol

_

__

_

+

PGE receptor

+

+

Gastrin receptor+

+

+

Page 28: Peptic Ulcer Disease( PUD):

Surgery: The cure of most peptic ulcers by H. pylori eradication &

availability of safe, potent acid-suppressing drugs have made elective surgery for PUD a rare event

Page 29: Peptic Ulcer Disease( PUD):

Complications: Perforation Ggastric outlet obstruction Bleeding

Page 30: Peptic Ulcer Disease( PUD):

PEPTIC ULCER DISEASE IN OLD AGE:

Gastroduodenal ulcers: have a greater incidence, admission rate & mortality.

Causes: high prevalence of H. pylori & NSAID use& impaired defence mechanisms.

Atypical presentations: pain &dyspepsia are frequently absent or atypical so older people develop complications such as bleeding or perforation more frequently.

Bleeding: older patients require more intensive management (including central venous pressure measurement) than younger patients because they tolerate hypovolaemic shock poorly.